Genetic Link Between Type 2 Diabetes and Cancer
Diabetes and cancer are often treated as two separate diseases, but new research suggests they are more connected than many realise. A recent large-scale genetic study has identified variants that raise the risk of both Type 2 diabetes and certain cancers, including breast, bowel, and pancreatic.
This discovery helps explain why people with diabetes are statistically more likely to develop cancer, and the importance of rethinking how we approach prevention.
Shared genetic pathways
For years, the link between Type 2 diabetes and cancer was largely attributed to lifestyle factors. Central obesity, high blood sugar, and chronic inflammation all create an environment in the body that promotes both metabolic disease and uncontrolled cell growth. While this remains true, the new findings show that genetics also play a significant role.
Some of the same genetic markers that influence how the body regulates glucose and insulin also affect how cells divide and repair. When these pathways are disrupted, the risk of both diabetes and certain cancers rises in parallel.
Diabetes is not just a metabolic disorder, and cancer is not just a genetic accident. They share deeper roots that must be addressed together.
Where conventional screening falls short
Standard screening tools are important, but they don’t always capture the full picture. HbA1c blood tests can detect diabetes once it has already developed, but they do not reveal the years of insulin resistance and metabolic stress that come beforehand. Likewise, cancer screening tests such as mammograms, PSA blood tests, or colonoscopies can only detect certain cancers, often at later stages.
Cancers like pancreatic, ovarian, and kidney currently have no routine screening pathways. Even where testing exists, false negatives and false positives remain a reality. This means many people at increased risk, including those with genetic predispositions, may go undetected until symptoms appear.
Functional medicine and advanced testing
At his private clinic, Dr Konrad Grosser takes a broader approach. By combining functional medicine with advanced personalised screening, he helps patients identify risks long before they become visible in standard tests.
Tools such as TruAge, which measures biological age and tracks how quickly the body is aging at a cellular level, and TruIntelli, a DNA/RNA-based multi-cancer screening test, are central to this approach. These technologies provide insight into both genetic predisposition and early biological changes, often years before symptoms arise.
Rather than treating conditions as isolated events, Dr Grosser uses these results to build a complete picture of a patient’s metabolic, genetic, and lifestyle profile. This allows for highly targeted prevention strategies, tailored to the individual.
Prevention through lifestyle and early intervention
Genetics may increase susceptibility, but they do not determine destiny. Functional medicine focuses on how lifestyle, environment, and medical support can influence gene expression and reduce disease risk.
For patients at higher risk of both diabetes and cancer, practical strategies include:
- Reducing abdominal fat through tailored nutrition and exercise programmes
- Stabilising blood sugar levels to limit the metabolic stress that drives both diabetes and cancer growth
- Supporting the body’s natural repair systems with anti-inflammatory diets, stress reduction, and sleep optimisation
- Using targeted therapies where appropriate to reset metabolic processes
Combined with advanced screening, these measures help patients take control of their health long before disease develops. Book a consultation with Dr Grosser today to find out more.
